AVACTA GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48 GBX | -3.52% |
|
-8.57% | -58.80% |
| Apr. 10 | Transcript : Avacta Group Plc - Special Call | |
| Apr. 09 | Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting | CI |
| Sales 2023 * | 23.08M 28.7M | Sales 2024 * | 26.12M 32.48M | Capitalization | 137M 170M |
|---|---|---|---|---|---|
| Net income 2023 * | -23M -28.6M | Net income 2024 * | -32M -39.79M | EV / Sales 2023 * | 5.21 x |
| Net cash position 2023 * | 16.2M 20.14M | Net cash position 2024 * | 7.3M 9.08M | EV / Sales 2024 * | 4.95 x |
| P/E ratio 2023 * |
-5.99
x | P/E ratio 2024 * |
-4.4
x | Employees | 120 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 69.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on Avacta Group Plc
More press releases
| 1 day | -3.52% | ||
| 1 week | -11.11% | ||
| Current month | -3.52% | ||
| 1 month | -8.13% | ||
| 3 months | -54.29% | ||
| 6 months | -64.76% | ||
| Current year | -58.80% |
1 week
47.25
53.00
1 month
47.2557.90
Current year
47.25119.85
1 year
47.25166.98
3 years
38.00291.80
5 years
13.00291.80
10 years
13.00291.80
| Managers | Title | Age | Since |
|---|---|---|---|
Alastair Smith
FOU | Founder | - | 03-12-31 |
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 16-01-03 |
Matt Johnson
CTO | Chief Tech/Sci/R&D Officer | - | 13-09-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Trevor Nicholls
BRD | Director/Board Member | 67 | 13-08-01 |
Alastair Smith
FOU | Founder | - | 03-12-31 |
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 16-01-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 48 | -3.52% | 2,784,767 |
| 24-04-17 | 49.75 | -1.97% | 1,924,478 |
| 24-04-16 | 50.75 | -1.46% | 1,482,004 |
| 24-04-15 | 51.5 | -0.48% | 1,811,185 |
| 24-04-12 | 51.75 | -1.43% | 1,928,256 |
Delayed Quote London S.E., April 18, 2024 at 11:35 am EDT
More quotes
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.48
GBP
Average target price
0.9233
GBP
Spread / Average Target
+92.36%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -58.80% | 176M | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- AVCT Stock
